Successful Management of Clozapine-induced Akathisia with Gabapentin Enacarbil: A Case Report
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event related to CLZ administration and thus the management of this syndrome is not well established. Here, we report a case of treatment-resistant schizophrenia wherein CLZ-induced akathisia was successfully managed with gabapentin enacarbil (GE). The patient was a 39-year-old woman who had been treated with atypical antipsychotics other than CLZ for three years with poor tolerability. Initiation of CLZ (400 mg/day) attenuated her psychotic symptoms, but was followed by moderate akathisia. Neither benzodiazepines nor biperiden improved the akathisia; however, akathisia was finally diminished with co-administration of GE. GE facilitated a dosage increase in CLZ (450 mg/day) for the improved management of pyschotic symptoms, and thus indirectly contributed to treatment of the patient’s schizophrenia. We suggest that GE is a useful candidate for the management of CLZ-induced akathisia. The improved management of treatment-induced akathisia and other adverse events can extend the potential application of CLZ for treatment-resistant schizophrenia.
Abstract
The management of clozapine (CLZ)-induced adverse events affects patient prognoses. Akathisia is a relatively rare adverse event related to CLZ administration and thus the management of this syndrome is not well established. Here, we report a case of treatment-resistant schizophrenia wherein CLZ-induced akathisia was successfully managed with gabapentin enacarbil (GE). The patient was a 39-year-old woman who had been treated with atypical antipsychotics other than CLZ for three years with poor tolerability. Initiation of CLZ (400 mg/day) attenuated her psychotic symptoms, but was followed by moderate akathisia. Neither benzodiazepines nor biperiden improved the akathisia; however, akathisia was finally diminished with co-administration of GE. GE facilitated a dosage increase in CLZ (450 mg/day) for the improved management of pyschotic symptoms, and thus indirectly contributed to treatment of the patient’s schizophrenia. We suggest that GE is a useful candidate for the management of CLZ-induced akathisia. The improved management of treatment-induced akathisia and other adverse events can extend the potential application of CLZ for treatment-resistant schizophrenia.
참고문헌 (12)
- Kane J, "Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine", Arch Gen Psychiatry, 45, pp.789~796 (1988)[DOI]
- Pfeffer G, "Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia", Int Clin Psychopharmacol, 20, pp.179~181 (2005)[DOI]
- Sullivan MA, "Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report", Ther Adv Psychopharmacol, 4, pp.100~102 (2014)[DOI]
- Van Putten T, "Why do schizophrenic patients refuse to take their drugs?", Arch Gen Psychiatry, 31, pp.67~72 (1974)[DOI]
- Yeon-Woo Lee, "Subjective Well-being in Patients with Schizophrenia Treated with Atypical Antipsychotics: The Impact of Psychopathology and Adverse Drug Effects", Clinical Psychopharmacology and Neuroscience, 8(3), pp.149~155 (2010), 대한정신약물학회
- Weiden PJ, "EPS profiles: the atypical antipsychotics are not all the same", J Psychiatr Pract, 13, pp.13~24 (2007)[DOI]
- Grover S, "Clozapine induced akathisia: a case report and review of the evidence", Indian J Pharmacol, 47, pp.234~235 (2015)[DOI]
- Aggarwal S, "Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implications", Curr Drug Saf, 10, pp.98~105 (2015)[DOI]
- Holloman LC, "Management of acute extrapyramidal effects induced by antipsychotic drugs", Am J Health Syst Pharm, 54, pp.2461~2477 (1997)
- Brown KW, "Low serum iron status and akathisia", Lancet, 1, pp.1234~1236 (1987)
- O'Hare JA, "Prevalence and forms of neuropathic morbidity in 800 diabetics", Ir J Med Sci, 163, pp.132~135 (1994)[DOI]
- Trenkwalder C, "Restless legs syndrome associated with major diseases: A systematic review and new concept", Neurology, 86, pp.1336~1343 (2016)[DOI]